Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH

Langerhans cell histiocytosis (LCH) is a disorder with a variety of clinical signs. The most severe forms affect risk organs (RO). The established role of the BRAF V600E mutation in LCH led to a targeted approach. However, targeted therapy cannot cure the disease, and cessation leads to quick relaps...

Descripción completa

Detalles Bibliográficos
Autores principales: Evseev, Dmitry, Osipova, Daria, Kalinina, Irina, Raykina, Elena, Ignatova, Anna, Lyudovskikh, Evelina, Baidildina, Dina, Popov, Alexander, Zhogov, Vladimir, Semchenkova, Alexandra, Litvin, Eugeny, Kotskaya, Natalia, Cherniak, Ekaterina, Voronin, Kirill, Burtsev, Eugeny, Bronin, Gleb, Vlasova, Irina, Purbueva, Bazarma, Fink, Olesya, Pristanskova, Ekaterina, Dzhukaeva, Irina, Erega, Elena, Novichkova, Galina, Maschan, Alexey, Maschan, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500470/
https://www.ncbi.nlm.nih.gov/pubmed/37216396
http://dx.doi.org/10.1182/bloodadvances.2022009067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500470/
https://www.ncbi.nlm.nih.gov/pubmed/37216396
http://dx.doi.org/10.1182/bloodadvances.2022009067

Ejemplares similares